	US 7,501,415 B2
	Selective inhibitors of ERK protein kinase and uses thereof
Alexander Aronov, Watertown, Mass. (US); Michael Hale, Bedford, Mass. (US); Francois Maltais, Tewksbury, Mass. (US); Gabriel Martinez-Botella, West Roxbury, Mass. (US); Judith Straub, Santa Cruz, Calif. (US); and Qing Tang, Acton, Mass. (US)
Assigned to Vertex Pharmaceuticals Incorporated, Cambridge, Mass. (US)
Filed on Dec. 20, 2005, as Appl. No. 11/312,618.
Claims priority of provisional application 60/638502, filed on Dec. 23, 2004.
Prior Publication US 2006/0160807 A1, Jul. 20, 2006
Int. Cl. C07D 403/04 (2006.01); A61K 31/506 (2006.01)

U.S. Cl. 514—241 [514/242; 514/255.05; 514/275; 544/182; 544/212; 544/295; 544/296; 544/330; 544/331]

7 Claims

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R¹is CH₃;

each R is independently selected from hydrogen or a C_1-6aliphatic group;

R²is R or halogen;

p is 0; and

R⁴is selected from NO₂, R, F, or Cl.